138,440 Shares in Boston Scientific Corporation $BSX Acquired by Clough Capital Partners L P

Clough Capital Partners L P acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 138,440 shares of the medical equipment provider’s stock, valued at approximately $13,200,000.

Other large investors have also recently modified their holdings of the company. Banco Bilbao Vizcaya Argentaria S.A. increased its stake in Boston Scientific by 29.0% during the 4th quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 135,150 shares of the medical equipment provider’s stock valued at $12,911,000 after purchasing an additional 30,365 shares in the last quarter. Boothbay Fund Management LLC increased its stake in Boston Scientific by 29.0% during the 4th quarter. Boothbay Fund Management LLC now owns 36,444 shares of the medical equipment provider’s stock valued at $3,475,000 after purchasing an additional 8,194 shares in the last quarter. Armistice Capital LLC increased its stake in Boston Scientific by 42.1% during the 4th quarter. Armistice Capital LLC now owns 114,025 shares of the medical equipment provider’s stock valued at $10,872,000 after purchasing an additional 33,802 shares in the last quarter. Align Financial LLC acquired a new position in Boston Scientific during the 4th quarter valued at approximately $1,249,000. Finally, Freestone Grove Partners LP increased its stake in Boston Scientific by 1,733.2% during the 4th quarter. Freestone Grove Partners LP now owns 1,327,239 shares of the medical equipment provider’s stock valued at $126,552,000 after purchasing an additional 1,254,840 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

BSX opened at $44.86 on Thursday. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The company has a market cap of $66.68 billion, a price-to-earnings ratio of 18.77, a PEG ratio of 0.90 and a beta of 0.56. Boston Scientific Corporation has a 52-week low of $44.79 and a 52-week high of $109.50. The firm’s fifty day simple moving average is $55.38 and its two-hundred day simple moving average is $73.62.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue was up 11.6% compared to the same quarter last year. During the same period last year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a share repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

A number of research analysts have issued reports on BSX shares. Mizuho cut their price target on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th. UBS Group dropped their price objective on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a report on Tuesday, March 17th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $55.00 price objective (down from $75.00) on shares of Boston Scientific in a report on Thursday, May 28th. Jefferies Financial Group dropped their price objective on shares of Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Finally, Zacks Research downgraded shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $85.08.

Insider Buying and Selling

In other news, Director David C. Habiger acquired 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the transaction, the director owned 13,878 shares in the company, valued at approximately $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Edward J. Ludwig purchased 3,580 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, with a total value of $202,914.40. Following the completion of the transaction, the director owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders bought 9,800 shares of company stock worth $554,012. Insiders own 0.34% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.